Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. May-Jun 2024;74(3):229-263.

Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10–45.

PubMed  PubMed Central  Google Scholar 

Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134(3):622–8.

Article  CAS  PubMed  Google Scholar 

Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7(32):52307–16.

Article  PubMed  PubMed Central  Google Scholar 

Koemans WJ, Lurvink RJ, Grootscholten C, Verhoeven RHA, de Hingh IH, van Sandick JW. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer. 2021;24(4):800–9.

Article  PubMed  Google Scholar 

Sirody J, Kaji AH, Hari DM, Chen KT. Patterns of gastric cancer metastasis in the United States. Am J Surg. 2022;224(1 Pt B):445–8.

Article  PubMed  Google Scholar 

Maehara Y, Moriguchi S, Kakeji Y, Kohnoe S, Korenaga D, Haraguchi M, et al. Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery. 1991;110(5):820–3.

CAS  PubMed  Google Scholar 

Rijken A, Pape M, Simkens GA, de Hingh I, Luyer MDP, van Sandick JW, et al. Peritoneal metastases from gastric cancer in a nationwide cohort: Incidence, treatment and survival. Int J Cancer. 2024;154(6):992–1002.

Article  CAS  PubMed  Google Scholar 

Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.

Article  CAS  PubMed  Google Scholar 

Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. investigators Ct. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(12):1389–96.

Article  CAS  PubMed  Google Scholar 

Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167–92.

Article  CAS  PubMed  Google Scholar 

Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2025 (7th edition). Gastric Cancer. 2026;29(2):271–299.

Solass W, Horvath P, Struller F, Konigsrainer I, Beckert S, Konigsrainer A, et al. Functional vascular anatomy of the peritoneum in health and disease. Pleura Peritoneum. 2016;1(3):145–58.

Article  PubMed  PubMed Central  Google Scholar 

Fujimori D, Kinoshita J, Yamaguchi T, Nakamura Y, Gunjigake K, Ohama T, et al. Established fibrous peritoneal metastasis in an immunocompetent mouse model similar to clinical immune microenvironment of gastric cancer. BMC Cancer. 2020;20(1):1014.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacquet P, Sugarbaker PH. Peritoneal-plasma barrier. Cancer Treat Res. 1996;82:53–63.

Article  CAS  PubMed  Google Scholar 

Kim H, Kwon M, Lee SK, Son SM, Lee OJ, Man Yoon S, et al. Distinct immunosuppressive tumor microenvironment in gastric cancer with peritoneal metastasis. J Gastric Cancer. 2025;25(4):605–20.

Article  PubMed  PubMed Central  Google Scholar 

Cortes-Guiral D, Hubner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K, Turaga KK, Chand M. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers. 2021;7(1):91.

Prabhu A, Mishra D, Brandl A, Yonemura Y. Gastric cancer with peritoneal metastasis-a comprehensive review of current intraperitoneal treatment modalities. Front Oncol. 2022;12:864647.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sammartino P, De Manzoni G, Marano L, Marrelli D, Biacchi D, Sommariva A, Scaringi S, Federici O, Guaglio M, Angrisani M, Cardi M, Fassari A, Casella F, Graziosi L, Roviello F. Gastric Cancer (GC) with Peritoneal Metastases (PMs): An Overview of Italian PSM Oncoteam Evidence and Study Purposes. Cancers (Basel). 2023;15(12):3137.

Acs M, Piso P, Glockzin G. Peritoneal metastatic gastric cancer: local treatment options and recommendations. Curr Oncol. 2024;31(3):1445–59.

Article  PubMed  PubMed Central  Google Scholar 

Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234–47.

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Shitara K, Ajani JA, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, Bruges R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Zander T, Kowalyszyn R, Pazo-Cid R, Schenker M, Feeny K, McCraith S, Hu N, Lei M, Zhang J, Moehler M. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649. Ann Oncol. 2026.

Oleson JR, Calderwood SK, Coughlin CT, Dewhirst MW, Gerweck LE, Gibbs FA Jr., et al. Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol. 1988;11(3):368–80.

Article  CAS  PubMed  Google Scholar 

van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh I, van der Velden J, Arts HJ, Massuger L, Aalbers AGJ, Verwaal VJ, Kieffer JM, Van de Vijver KK, van Tinteren H, Aaronson NK, Sonke GS. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–240.

Mirnezami R, Mehta AM, Chandrakumaran K, Cecil T, Moran BJ, Carr N, et al. Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer. 2014;111(8):1500–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Graf W, Ghanipour L, Birgisson H, Cashin PH. Cytoreductive Surgery and Hyperthermic intraperitoneal chemotherapy for peritoneal metastases from colorectal cancer-an overview of current status and future perspectives. Cancers (Basel). 2024;16(2):284.

Tonello M, Cenzi C, Pizzolato E, Martini M, Pilati P, Sommariva A. National guidelines for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal malignancies: A worldwide systematic review and recommendations of strength analysis. Ann Surg Oncol. 2025;32(8):5795–806.

Article  PubMed  PubMed Central  Google Scholar 

Pelc Z, Sedlak K, Endo Y, Van Sandick J, Gisbertz S, Pera M, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal metastasis - joint analysis of European GASTRODATA and American national cancer database. Am J Surg. 2025;242:116235.

Article  PubMed  Google Scholar 

Tops-Welten MW, Galanos LJK, Creemers GJ, Luyer MDP, De Hingh I, van Hellemond IEG. Gastrointestinal CancerEmerging treatment modalities for gastric cancer with peritoneal metastases: a systematic review. Oncologist. 2025;30(9):oyaf219.

Rau B, Lang H, Koenigsrainer A, Gockel I, Rau HG, Seeliger H, et al. Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial. J Clin Oncol. 2024;42(2):146–56.

Article  CAS  PubMed  Google Scholar 

Quik JS. PERISCOPE II Trial: Randomized study finds no OS advantage for gastrectomy plus CRS/HIPEC versus systemic therapy. ESMO, Proceedings. 2025.

Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20(2):367–73.

Article  PubMed  Google Scholar 

Rahimi-Gorji M, Van de Sande L, Debbaut C, Ghorbaniasl G, Braet H, Cosyns S, et al. Intraperitoneal aerosolized drug delivery: technology, recent developments, and future outlook. Adv Drug Deliv Rev. 2020;160:105–14.

Article  CAS  PubMed  Google Scholar 

Alyami M, Hubner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–77.

Article  PubMed  Google Scholar 

Struller F, Horvath P, Solass W, Weinreich FJ, Strumberg D, Kokkalis MK, et al. Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study. Ther Adv Med Oncol. 2019;11:1758835919846402.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alyami M, Bonnot PE, Mercier F, Laplace N, Villeneuve L, Passot G, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol. 2021;47(1):123–7.

Article